🔴 Corcept Therapeutics is trading 4.54% down in pre-market after management reiterated 2026 revenue guidance

Corcept Therapeutics is trading at $75.62, down 4.54%, as investors focused on management reiterating 2026 revenue guidance rather than raising it.

• Q3 revenue was $340.5 million and adjusted earnings per share were $1.01, both above analyst estimates.
• Shares fell 3.31% at the November 4 close.
• Biotech shares were higher in the supplied pre-market context, so the sector trend does not explain this move.